Larger shareholder and board member transfer subscription rights free of charge to qualified investors
The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the authorization from the Annual General Meeting on May 5, 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million (the “Rights Issue”). In connection with the Rights Issue, the Company's second largest shareholder, Sunstone Life Science Ventures Fund II K/S, and board member Carl Borrebaeck have, at the request of qualified investors and in consultation with the Company's financial